NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free ATRC Stock Alerts $22.54 +0.28 (+1.26%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share Today's Range$22.20▼$23.5550-Day Range$20.69▼$30.4252-Week Range$20.19▼$59.61Volume704,100 shsAverage Volume700,399 shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$49.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AtriCure alerts: Email Address AtriCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside120.8% Upside$49.78 Price TargetShort InterestBearish6.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.09Based on 10 Articles This WeekInsider TradingSelling Shares$504,932 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.75) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsMedical Sector434th out of 924 stocksSurgical & Medical Instruments Industry56th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has only been the subject of 4 research reports in the past 90 days.Read more about AtriCure's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.49% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 3.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 3.4 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for AtriCure this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold 353.87% more of their company's stock than they have bought. Specifically, they have bought $111,250.00 in company stock and sold $504,932.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.75) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -28.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -28.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About AtriCure Stock (NASDAQ:ATRC)AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesJune 1 at 9:23 AM | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Insider Purchases $111,250.00 in StockMay 4, 2024 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Insider Sells $36,135.00 in StockJune 2 at 6:42 AM | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Insider Salvatore Privitera Buys 5,000 SharesJune 1 at 3:18 AM | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Receives $49.78 Average PT from BrokeragesMay 31 at 8:05 PM | gurufocus.comInsider Buying: Chief Technical Officer Salvatore Privitera Acquires Shares of AtriCure Inc (ATRC)May 15, 2024 | businesswire.comAtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads ConferenceMay 4, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price TargetMay 3, 2024 | markets.businessinsider.comAtricure’s Strong Performance and Growth Potential Affirm Buy RatingMay 3, 2024 | finance.yahoo.comAtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | finance.yahoo.comThe past three years for AtriCure (NASDAQ:ATRC) investors has not been profitableMay 2, 2024 | markets.businessinsider.comAtricure’s Growth and Resilience Reinforce Buy RatingMay 2, 2024 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comAtriCure’s Strong Growth and Market Position Justify Buy RatingMay 2, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 1, 2024 | investorplace.comATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comAtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider LossesMay 1, 2024 | businesswire.comAtriCure Reports First Quarter 2024 Financial ResultsApril 30, 2024 | markets.businessinsider.comAtriCure is about to announce its earnings — here's what Wall Street expectsApril 30, 2024 | businesswire.comAtriCure to Participate in the 2024 Bank of America Securities Healthcare ConferenceApril 23, 2024 | msn.comAtriCure upgraded at Oppenheimer on valuationApril 22, 2024 | finance.yahoo.comAtriCure, Inc. (ATRC) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | nasdaq.comFirst Week of June 21st Options Trading For AtriCure (ATRC)April 20, 2024 | investing.comAtriCure launches advanced cryoablation probe to expedite surgeriesApril 18, 2024 | businesswire.comAtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain ManagementApril 10, 2024 | businesswire.comAtriCure to Announce First Quarter 2024 Financial ResultsSee More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/03/2024Next Earnings (Estimated)7/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,200Year Founded2000Price Target and Rating Average Stock Price Target$49.78 High Stock Price Target$68.00 Low Stock Price Target$32.00 Potential Upside/Downside+120.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,440,000.00 Net Margins-8.98% Pretax Margin-8.81% Return on Equity-7.85% Return on Assets-6.05% Debt Debt-to-Equity Ratio0.16 Current Ratio4.00 Quick Ratio2.83 Sales & Book Value Annual Sales$399.24 million Price / Sales2.69 Cash FlowN/A Price / Cash FlowN/A Book Value$9.59 per share Price / Book2.35Miscellaneous Outstanding Shares47,590,000Free Float46,065,000Market Cap$1.07 billion OptionableOptionable Beta1.41 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 53)CEO, President & Director Comp: $2.01MMs. Angela L. Wirick CPA (Age 46)Chief Financial Officer Comp: $841.54kMr. Douglas J. Seith (Age 58)Chief Operating Officer Comp: $1.2MMr. Salvatore Privitera J.D. (Age 57)Chief Technical Officer Comp: $758.8kMr. Karl S. Dahlquist CCEP (Age 53)J.D., Chief Legal Officer Comp: $762.39kDr. Vinayak Doraiswamy Ph.D. (Age 52)Chief Scientific Officer Comp: $777.66kValerie Storch-WillhausVice President of Corporate Marketing & CommunicationsMr. Justin J. Noznesky (Age 46)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 58)Chief Human Resources Officer Comp: $498.36kMore ExecutivesKey CompetitorsCardiovascular SystemsNASDAQ:CSIIAtrionNASDAQ:ATRIPulmonxNASDAQ:LUNGInovio PharmaceuticalsNASDAQ:INONuVasiveNASDAQ:NUVAView All CompetitorsInsiders & InstitutionsSalvatore PriviteraBought 5,000 shares on 5/30/2024Total: $111,250.00 ($22.25/share)Comerica BankBought 1,043 shares on 5/17/2024Ownership: 0.005%Grandeur Peak Global Advisors LLCBought 113,480 shares on 5/16/2024Ownership: 0.725%Silvercrest Asset Management Group LLCSold 67,315 shares on 5/16/2024Ownership: 0.400%California State Teachers Retirement SystemSold 2,517 shares on 5/16/2024Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions ATRC Stock Analysis - Frequently Asked Questions Should I buy or sell AtriCure stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks. What is AtriCure's stock price target for 2024? 7 equities research analysts have issued 1 year price objectives for AtriCure's stock. Their ATRC share price targets range from $32.00 to $68.00. On average, they anticipate the company's stock price to reach $49.78 in the next twelve months. This suggests a possible upside of 120.8% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts. How have ATRC shares performed in 2024? AtriCure's stock was trading at $35.69 at the beginning of 2024. Since then, ATRC stock has decreased by 36.8% and is now trading at $22.54. View the best growth stocks for 2024 here. When is AtriCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024. View our ATRC earnings forecast. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Wednesday, May, 1st. The medical device company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The medical device company earned $108.90 million during the quarter, compared to analyst estimates of $106.86 million. AtriCure had a negative trailing twelve-month return on equity of 7.85% and a negative net margin of 8.98%. The firm's quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) EPS. What ETF holds AtriCure's stock? iShares U.S. Medical Devices ETF holds 314,124 shares of ATRC stock, representing 0.14% of its portfolio. What guidance has AtriCure issued on next quarter's earnings? AtriCure issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of -0.820--0.740 for the period, compared to the consensus EPS estimate of -0.740. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $461.3 million. What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). Who are AtriCure's major shareholders? AtriCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.99%), Champlain Investment Partners LLC (5.63%), First Light Asset Management LLC (2.91%), TimesSquare Capital Management LLC (1.80%), Wasatch Advisors LP (1.49%) and Bellevue Group AG (0.94%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Salvatore Privitera, Tonya Austin and Vinayak Doraiswamy. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More This page (NASDAQ:ATRC) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.